Shares of Schrödinger, Inc. (NASDAQ:SDGR – Get Free Report) have received a consensus rating of “Moderate Buy” from the nine research firms that are currently covering the stock, Marketbeat reports. Three investment analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $40.89.
Several analysts have recently weighed in on SDGR shares. Citigroup dropped their price target on shares of Schrödinger from $39.00 to $37.00 and set a “buy” rating for the company in a research note on Thursday, May 2nd. Craig Hallum dropped their price target on shares of Schrödinger from $35.00 to $30.00 and set a “buy” rating for the company in a research note on Thursday, May 2nd.
Check Out Our Latest Stock Analysis on SDGR
Hedge Funds Weigh In On Schrödinger
Schrödinger Trading Down 3.0 %
SDGR stock opened at $18.76 on Tuesday. The company has a market cap of $1.36 billion, a price-to-earnings ratio of -9.98 and a beta of 1.53. Schrödinger has a 12 month low of $18.21 and a 12 month high of $59.24. The firm has a 50-day moving average of $21.94 and a two-hundred day moving average of $26.29.
Schrödinger (NASDAQ:SDGR – Get Free Report) last released its quarterly earnings data on Wednesday, May 1st. The company reported ($0.76) EPS for the quarter, meeting analysts’ consensus estimates of ($0.76). Schrödinger had a negative net margin of 75.94% and a negative return on equity of 29.25%. The company had revenue of $36.60 million during the quarter, compared to the consensus estimate of $41.23 million. As a group, equities analysts forecast that Schrödinger will post -2.7 earnings per share for the current year.
About Schrödinger
Schrödinger, Inc, together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries.
Further Reading
- Five stocks we like better than Schrödinger
- How is Compound Interest Calculated?
- These Top 3 Banks Raise Dividends After Passing Fed Stress Test
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Hitch a Ride with Lyft Stock for Double-Digit Gains in 2nd Half
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Receive News & Ratings for Schrödinger Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Schrödinger and related companies with MarketBeat.com's FREE daily email newsletter.